For the quarter ending 2026-03-31, RGBP made $59,065 in revenue. $991,927 in net income. Net profit margin of 1679.38%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net revenue | 59,065 | 59,065 | 59,366* | 59,065 |
| Research and development | 2,216 | 210,000 | 11,725* | 0 |
| General and administrative | 32,104 | 231,925 | 9,045.5* | 30,697 |
| Consulting and professional fees | 178,454 | 153,764 | 123,478* | 46,624 |
| Rent | 0 | 15,000 | 22,500* | 22,500 |
| Total operating expenses | 212,774 | 610,689 | 166,748.5* | 99,821 |
| Profit (loss) from operations | -153,709 | -551,624 | -107,382.5* | -40,756 |
| Interest expense | 27,388 | 26,553 | 87,835.5* | 24,638 |
| Interest expense attributable to amortization of discount | 8,656 | 8,850 | 14,231* | 12,639 |
| Derivative income (expense) | 1,181,680 | -380,826 | -772,584* | -89,259 |
| Penalties | 0 | 0 | 12,500* | - |
| Financing fees | 0 | 0 | - | - |
| Total other income (expense), net | 1,145,636 | -416,229 | -887,150.5* | -126,536 |
| Net profit (loss) before income taxes | 991,927 | -967,853 | -994,533* | -167,292 |
| Income tax provision | 0 | 0 | 0* | 0 |
| Net profit (loss) | 991,927 | -967,853 | -994,533 | -167,292 |
| Basic EPS | 0 | -0.01 | -0.039 | -0.01 |
| Diluted EPS | 0 | -0.01 | -0.039 | -0.01 |
| Basic Average Shares | 184,943,349 | 99,609,650 | 25,258,700 | 23,752,506 |
| Diluted Average Shares | 184,943,349 | 99,609,650 | 25,258,700 | 23,752,506 |
Regen BioPharma Inc (RGBP)
Regen BioPharma Inc (RGBP)